HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics

Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

By BioPharma Dive · Apr 24, 2026 · via BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
moneyformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Roche Sits Out $29B Pharma Buying Frenzy, Citing Debt and Discipline
Money
Roche Sits Out $29B Pharma Buying Frenzy, Citing Debt and Discipline
As peers spent $29B in late-March M&A, Roche CEO Thomas Schinecker said high rates, no patent cliffs, and 19 d…
Apr 27, 2026
Avalyn’s $182M IPO: Leaning on Re‑Formulation to Reprice Old IPF Drugs
Money
Avalyn’s $182M IPO: Leaning on Re‑Formulation to Reprice Old IPF Drugs
Avalyn Pharma plans a $182M IPO to fund late‑stage trials for inhaled pirfenidone and nintedanib, signaling in…
Apr 25, 2026
Odyssey Therapeutics will try again to IPO, this time in a warmer market
MoneyEndpoints News ↗
Odyssey Therapeutics will try again to IPO, this time in a warmer market
A year after pulling its first try at an IPO, Odyssey Therapeutics is giving it another go. On Friday night, t…
Apr 20, 2026